GLX Analytix is an award-winning Silicon Valley venture- and strategic-backed personalized medicine company, pioneering a groundbreaking diagnostics and monitoring platform. Its proprietary GLX Signature Platform is powered by novel vascular biology and AI technology, designed to transform the care of patients with neurodegenerative, autoimmune, cardiovascular, and psychiatric diseases. Leveraging advanced glycobiology research and a new class of blood biomarkers, GLX Analytix also delivers innovative solutions for therapeutic strategies. With partnerships at leading medical institutions in the United States and Europe, the company aims to accelerate noninvasive, cost-effective, and highly accessible personalized care for patients worldwide. Recognized by industry leaders, GLX Analytix is poised to revolutionize early detection and treatment monitoring in conditions such as Alzheimer’s Disease, Multiple Sclerosis, ALS, and Major Depressive Disorder.